Insider Buying: Geron (NASDAQ:GERN) EVP Acquires $11,280.00 in Stock

Geron Corporation (NASDAQ:GERN – Get Free Report) EVP Timothy Williams purchased 12,000 shares of the stock in a transaction on Monday, November 16th. The shares were purchased at an average price of $0.94 per share, with a total value of $11,280.00. Following the acquisition, the executive vice president owned 12,000 shares in the company, valued at approximately $11,280. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Geron Trading Down 2.6%

Geron stock traded down $0.03 during trading hours on Monday, reaching $0.94. 9,306,519 shares of the company’s stock were exchanged, compared to its average volume of 14,085,533. The firm’s 50 day simple moving average is $1.18 and its 200 day simple moving average is $1.40. Geron Corporation has a twelve month low of $0.84 and a twelve month high of $2.01. The firm has a market capitalization of $606.81 million, a PE ratio of -11.77 and a beta of 0.62. The company has a quick ratio of 4.61, a current ratio of 6.31 and a debt-to-equity ratio of 0.53.

Institutional Trading of Geron

Hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP bought a new stake in shares of Geron during the third quarter valued at approximately $1,406,000. Nantahala Capital Management LLC boosted its stake in shares of Geron by 13.5% during the third quarter. Nantahala Capital Management LLC now owns 13,873,533 shares of the biopharmaceutical company’s stock valued at $17,064,000 after purchasing an additional 1,648,533 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Geron by 297.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 611,614 shares of the biopharmaceutical company’s stock worth $752,000 after acquiring an additional 457,674 shares in the last quarter. R Squared Ltd increased its holdings in shares of Geron by 52.7% during the third quarter. R Squared Ltd now owns 54,324 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 18,744 shares in the last quarter. Finally, Nan Fung Trinity HK Ltd. lifted its position in Geron by 83.2% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 2,223,550 shares of the biopharmaceutical company’s stock worth $2,735,000 after acquiring an additional 1,009,930 shares during the period. Institutional investors own 73.71% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on GERN shares. Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 9th. Wedbush dropped their price objective on shares of Geron to $5.00 and set an “outperform” rating for the company in a report on Wednesday, October 28th. Finally, Needham & Company LLC reduced their price objective on Geron from $4.00 to $2.50 and set a “buy” rating on the stock in a research note on Wednesday, October 28th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Geron has a consensus rating of “Hold” and a consensus target price of $3.75.

Get Our Latest Stock Report on Geron

Geron Company Profile

(Get Free Report)

Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.

Recommended Stories

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.